AstraZeneca is trading 3.23% down at $154.99 after reports that it is negotiating a potential licensing deal with Summit Therapeutics for ivonescimab, potentially valued at $15 billion.
- The proposed transaction could require a multibillion-dollar upfront payment, raising concerns about deal economics despite the drug’s lung-cancer opportunity.
- Major U.S. indexes finished higher on September 11, 2026, suggesting company-specific pressure rather than broad risk-off selling.
- No earnings release was identified for September 11.